Literature DB >> 20300975

The invasive malignancy from peritoneal epithelial cell: a report of four cases and review of literature.

Xue Hongjian1, Fan Jiquan, Peng Gang, Cao Rubo.   

Abstract

To analyze the clinical characteristics, diagnosis and treatment of primary peritoneal carcinoma (PPC) and to review the literature, so as to raise the awareness of the disease. Four cases of PPC diagnosed in our department from March 2005 to September 2007 were retrospectively analyzed. Four cases were all treated with platinum-based chemotherapy. They were treated with intraperitoneal chemohyperthermia (IPCH) with cisplatin, carboplatin or oxaliplatin with a closed sterile circuit of 1,000 ml physiologic saline and inflow temperature is 43°C, while they were receiving high-intensity focused microwave hyperthermia (HIFMH) concomitantly. Intravenous paclitaxel or docetaxel was used in three patients, while cyclophosphamide and adriamycin injection in another patient. After two cycles of chemotherapy, ascites decreased significantly or even disappeared. Up to 6 January 2010, the four cases had survived for 38, 51, 33 and 29 months, respectively. PPC is a group of invasive malignancy derived from the peritoneal epithelium, it is common in women and is homogeneous with ovarian cancer in pathology. Diagnosis relies mainly on postoperative pathologic diagnosis and cytology after ruling out ovarian cancer and gastrointestinal cancer. Platinum-containing chemotherapy, IPCH and the administration of taxanes can improve the overall response rate and long-term survival.

Entities:  

Mesh:

Year:  2010        PMID: 20300975     DOI: 10.1007/s12032-010-9471-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  14 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report.

Authors:  M SWERDLOW
Journal:  Am J Obstet Gynecol       Date:  1959-01       Impact factor: 8.661

3.  Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer.

Authors:  G H Eltabbakh; M S Piver; N Natarajan; C J Mettlin
Journal:  Obstet Gynecol       Date:  1998-02       Impact factor: 7.661

4.  Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?

Authors:  A Ayhan; C Taskiran; N Yigit-Celik; G Bozdag; M Gultekin; A Usubutun; N Guler; K Yuce
Journal:  Int J Gynecol Cancer       Date:  2006 Mar-Apr       Impact factor: 3.437

5.  Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.

Authors:  R Halperin; S Zehavi; R Langer; E Hadas; I Bukovsky; D Schneider
Journal:  Int J Gynecol Cancer       Date:  2001 Sep-Oct       Impact factor: 3.437

6.  Primary papillary serous carcinoma of the peritoneum in a man.

Authors:  E Shmueli; L Leider-Trejo; I Schwartz; D Aderka; M Inbar
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

7.  Prognostic factors in extraovarian primary peritoneal carcinoma.

Authors:  G H Eltabbakh; B A Werness; S Piver; L E Blumenson
Journal:  Gynecol Oncol       Date:  1998-11       Impact factor: 5.482

8.  Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma.

Authors:  S E Mills; W A Andersen; R E Fechner; M B Austin
Journal:  Am J Surg Pathol       Date:  1988-11       Impact factor: 6.394

9.  Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study.

Authors:  Jeffrey D Bloss; Mark F Brady; Shu Yuan Liao; Thomas Rocereto; Edward E Partridge; Daniel L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2003-04       Impact factor: 5.482

10.  Ovarian involvement by serous surface papillary carcinoma.

Authors:  T J Mulhollan; E G Silva; C Tornos; C Guerrieri; G L Fromm; D Gershenson
Journal:  Int J Gynecol Pathol       Date:  1994-04       Impact factor: 2.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.